Oxymetazoline nasal spray added to fluticasone for mild sleep apnea with stuffy nose
Tests oxymetazoline plus fluticasone in adults with mild sleep apnea and persistent nasal congestion.
Key facts
- Who runs it
- University of South Florida
- Where
- Tampa, United StatesSee the site
- Trial code
- Registry title
- Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 52 people, planned
- Started
- 1 Apr 2023
- Planned end
- Apr 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Oxymetazoline Hydrochloride
- Placebo
- Record updated
- 24 January 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with year-round allergic or non-allergic nasal inflammation and mild obstructive sleep apnea. Their stuffy nose must continue despite top doses of a steroid nasal spray.
- Age
- 18 to 65 years
- Sex
- Male and female
- Disease stage
- At least a 1 year history of year-round allergic or non-allergic rhinitis. Mild obstructive sleep apnea: AHI per hour of sleep > 5 and <15, minimum SpO2 88. Moderate to severe nasal congestion (average Nasal Congestion VAS > 3-10; Congestion Quantifier 7 score of 7).
- Earlier treatment
- Must have used the highest usual dose of a steroid nasal spray (NGCS) for at least 1 month. Cannot have had systemic glucocorticosteroids for 1 month before or during the study. Cannot need CPAP therapy.
Main reasons for not taking part
- Allergy to oxymetazoline or fluticasone propionate
- Pregnant or breastfeeding women
- Sinusitis, nasal polyps or major nose structure problems
- Central sleep apnea, moderate to severe OSA (AHI > 15), or SpO2 <88 for > 5 min during sleep
- Uncontrolled high blood pressure, heart rhythm problems, heart failure, or insulin-dependent diabetes
The registry criteria, word for word
Show all 30 criteriaShow less
Who can take part
- Male and female subjects 18 - 65 years of age
- At least a one year history of perennial allergic or non-allergic rhinitis
- Subjects must be on the maximum recommended doses of one of the following NGCS for at least one month. (See Table I)
- AHI per hour of sleep > 5 and <15, minimum SpO2 88, indicating mild obstructive sleep apnea)
- Average Nasal Congestion VAS of > 3-10 indicating moderate to severe nasal congestion between visits 1 and 2 based on daily symptoms (average of 7 scores)
- Average Congestion Quantifier 7 score of 7 between visits 1 and 2 based on weekly symptoms (average of 2 scores)
- Willingness to participate as indicated by signed informed consent
Who cannot take part
- Subjects receiving allergen immunotherapy but not on a stable maintenance regimen for at least 30 days before the first study visit
- If the subject has perennial allergic rhinitis, he/she should not be entered into this study eight weeks before, during, or six weeks after any seasonal exacerbation
- No systemic glucocorticosteroids for one month prior or during the study
- Subjects who are currently abusing alcohol, illicit drugs, benzodiazepines, or narcotics
- Use of the following medications within the time period specified below prior to Day -7 (Table 2)
- Presence of hypersensitivity to oxymetazoline or fluticasone propionate
- Other known nasal diseases likely to affect deposition of oxymetazoline such as sinusitis, nasal polyps, or major nasal structural malformations
- Respiratory tract infections in the last 14 days
- Infections requiring antibiotics in the last 14 days
- Asthma or chronic obstructive pulmonary disease (COPD) requiring roflumilast or more than the recommended doses of inhaled corticosteroids, beta agonists, or antimuscarinic agents
- Cardiovascular disease with uncontrolled hypertension (BP160/80), arrhythmias and/or congestive heart failure
- Insulin-dependent diabetes mellitus and/or diabetic retinopathy
- Hypertension requiring more than two drugs, with the exception of hydrochlorothiazide, to achieve control
- A history of drug or alcohol abuse within the past 5 years
- A history of benign prostate hypertrophy necessitating treatment
- A history of psychiatric problems which, in the opinion of the investigators, would impair participation in the study
- Subjects with obstructive sleep apnea syndrome requiring CPAP therapy
- Women who are pregnant or lactating
- Subjects with mild OSA (AHI 5-14) and SpO2 <88 for > 5 min during sleep that is identified during the screening portable sleep study
- Inability to cooperate, comply with study procedures or communicate with the investigator to successfully complete the study
- Subjects with a planned hospitalization during the study
- An infirmity, disability, or geographical location which seems likely to prevent regular attendance for subject visits
- Subjects diagnosed with central sleep apnea (> 5 central events per hour) or moderate to severe OSA (AHI > 15) and SpO2 <88 for > 5 min during sleep identified during screening
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in United States
- Usf Asthma Allergy and Immunology CruTampa, United StatesContact: Catherine SmithTaking people
About the trial
What the trial wants to find out
The addition of intranasal oxymetazoline for two weeks to already instituted optimal doses of intranasal fluticasone propionate will decrease the total number of obstructive apneas and hypopneas per hour of sleep in subjects with perennial allergic or non-allergic rhinitis and mild obstructive sleep apnea who have persistent nasal congestion despite maximum doses of NGCS.
The 2 groups in the trial
- Placebo/Fluticasone PropionatePlacebo, for comparison
Placebo Spray 2 Sprays QHS Fluticasone Propionate 1 spray BID
Treatment: Placebo
- Oxymetazoline Hydrochloride /Fluticasone PropionateExisting treatment, for comparison
Oxymetazoline Hydrochloride 2 Sprays QHS Fluticasone Propionate 1 spray BID
Treatment: Oxymetazoline Hydrochloride
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea. A Double Blinded Placebo Controlled, Crossover Prospective Trial.
- Plain-language title
- Oxymetazoline nasal spray added to fluticasone for mild sleep apnea with stuffy noseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT02630121, who can take part
- Record updated
- 24 January 2025